# Baylor College of Medicine: Phase 1 study closed enrollment, 27 enrolled (Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | Baylor College of Medicine |
| Sponsor type | Academic and hospital |
| Study | Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas |
| NCT ID | NCT04288726 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma |
| Intervention types | biological |
| Target enrollment | 27 |
| Site countries | United States |
| Posted | 2020-02-28 |
| Planned start | 2020-09-16 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-02 |
| Last update posted | 2026-10-02 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04288726). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.